

Department of Retrovirology - Protocol Titles

Protocols, Completed	Year Started	Year Ended
RV068 - Phase I Safety and Immunogenicity of a Recombinant Envelop Based Product in Thai Volunteers with Early HIV Infection (aborted)	1992	1993
RV069 - Phase I Safety and Immunogenicity of a Recombinant Envelop Based Product in HIV Seronegative Thai Volunteers (aborted)	1992	1993
RV091 - The Natural History of HIV-1 Infection and Disease in Thailand	1992	2001
RV093 - Immunologic Characterization of a Cohort of HIV-1 Highly Exposed Persistently Seronegative (HEPS) Individuals in Northern Thailand	1993	1996
RV099 - Clinical Study Protocol V6P17: A Phase I Trial of Biocine HIV SF2 gp120/MF59 Vaccine in Seronegative Thai Volunteers	1995	1997
RV101 - Screening and Evaluation of Potential Volunteers for HIV-1 Vaccine Trials	1999	2001
RV102 - Study of Prevalence and Incidence for HIV-1 Infections Among Eligible Thai Men in the Royal Thai Army at Prachuap Khiri Khan	1994	1997
RV104 - Incidence of HIV-1 Infection in Persons Attending Anonymous Test Sites and STD Clinics in Thailand	1994	1997
RV105 - Feasibility Study for Vaccine Cohort Development: Factory Workers Lampang	1995	1998
RV106 - Feasibility Study for Vaccine Cohort Development: Community-Based Study in Phayao	1995	1998
RV109 - Evaluation of HIV-1 Viral Burden, Mucosal Immunity and Systemic Immunity in Maternal-Infant Transmission in Northern Thailand	1998	2000
RV110 - Evaluation of HIV Infection in Vaccine Trial Participants in Thailand Follow-up Vaccine Trials (aborted)	1999	2000
RV114 - A Phase I/II Double-blind, Placebo-controlled Study of the Chiron Biocine HIV Thai E gp120/MF59 Vaccine Administered Alone or Combined with the Chiron Biocine HIV SF2gp120 Antigen in Healthy HIV Seronegative Thai Adults V26/6P1	1993	1995
RV115 - Health Evaluation HIV Infected of Thai Men 4 to 6 years After Discharge from the Royal	1998	2003
RV118 - Evaluation of the Mucosal Virology and Immunology of HIV-1 in Thailand	1998	2003
RV121 - Incidence of HIV-1 Infection in Females Attending Family Planning Clinics in Rayong Province, Thailand	1996	2001
RV126 - Community Based Cohort Study of HIV-1 Incidence in Thailand WRAIR # 673	1994	2003
RV127 - Community Cohort Studies to Identify Appropriate Populations for HIV-1 Vaccine	1994	2003
RV132 - Phase I/II Trial of Pasteur Mérieux Connaught Live Recombinant ALVAC-HIV (vCP1521) Priming With Either Oligomeric gp160 TH023/LAI-DID or Chiron HIV Thai E (CM235) gp120 [+/- SF2 gp120] Boosting in Thai HIV-Seronegative Adults IND# 8590	2000	2002
RV133 - A Pilot Study of Scrub Typhus-Induced Immunoneutralization of the HIV-1 Virus	1999	2000
RV135 - A Phase I/II Trial of Pasteur Mérieux Connaught (PMC) Live Recombinant ALVAC-HIV (vCP1521) Priming With VaxGen gp120 B/E (AIDSVAX™ B/E) Boost in Thai HIV-Seronegative Adults NID #8795	2000	2002
RV140 - Screening and Evaluation of Potential Volunteers for HIV-1 Vaccine Trials in Thailand (aborted)		
RV144 - A phase 3 trial of Aventis Pasteur live recombinant ALVAC HIV (vCP1521) priming with Vaxgen gp120 B/E (AIDSVAX B/E) Boosting HIV uninfected Thai adults IND #8795	2003	2009
RV148 - Screening protocol for the phase 3 vaccine trial	2003	2006
RV156 - VRC-HIVDNA009-VP (Multiclade HIV-1 DNA Plasmid Vaccine)	2005	2008
RV158 - A Phase I Double-Blind, Randomized, Dose Escalating, Placebo-Controlled, Study of Safety and Immunogenicity of WRAIR/NIH Live Recombinant MVACMDR (HIV-1 CM235 env/CM240 gag/pol) Administered by Intramuscular (IM) or Intradermal (ID) Route In HIV Uninfected Adults	2005	2008
RV172 - A Phase 2 Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid, VRCHIVDNA016-00-VP, Boosted by Multiclade HIV-1 Recombinant Adenovirus-5 Vaccine, VRC-HIV ADV014-00-VP in HIV Uninfected Adult Volunteers in East Africa	2007	2009
RV174 - The Effect of the HLA B46 Allele on the Natural History and Progression of HIV-1 Infection in Thailand	2007	2010
RV181 Randomized, Double Blind HIV Vaccine Trial to Evaluate the Immune Profile of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming with VaXGen gp120 B/E (AIDSVAX® B/E) Boosting HIV Uninfected Thai Adults (aborted)		
RV188 New laboratory techniques for the evaluation of the cellular and humoral immunity in HIV-Infected and non-infected Thai Individuals to HIV antigens and HIV vaccine reagents (aborted)		
RV225 - Molecular Epidemiology (Genotyping and Sequencing) of HIV from High-risk Client at	2007	2009

RV233 (SEARCH 08) - Development of High-risk HIV Vaccine Preparatory Cohort at Thai Red Cross	2008	2010
RV250 - Multi-region Hybridization Assay Adaptation, Automation and Validation Using Dried Blood Spots for the Surveillance of HIV-1 Strains in South and Southeast Asia	2010	2011
WR # 1161 (SEARCH001) - Predictors of Neuro-cognitive Decline and Survival in HIV-infected Subjects (UH-PMK NeuroAIDS Study 001)	2006	2007
WR # 1307 (SEARCH 004) - Preliminary study of early primary HIV infection in high risk cohort	2006	2007
WR # 1708 - Comparative Study of FcR-Mediated Antibody Effector Assays for HIV-1	2010	2010

Protocols, Currently Implemented	Year Started
RV152 - Extended evaluation of the virologic, immunologic, and clinical course of volunteers who become HIV-1 infected during participation in a phase III vaccine trial of ALVAC-HIV and AIDSVAX® B/E	2005
RV209 - Immunological assessment of RV135, A phase I/II of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming with VaxGen 120 B/E (AIDSVAX B/E) Boosting in Thai-Seronegative Adults, using recently validated immuno-monitoring assays	2006
RV212 (IAVI Protocol G) - A cross-sectional study to screen for generate broadly neutralizing monoclonal antibodies from HIV Infected Individuals	2007
RV217d - Study of Prevalence and Incidence of HIV Among High-risk Volunteers in East Africa and Thailand (Pattaya)	2009
RV237 - Development and Characterization of Reagents for Studies of HIV-1 Neutralization from Archived Cell and Plasma Samples	2008
RV238 (SEARCH 007) - HIV-1 Specific Immune Responses in Thai Individuals with HIV	2008
RV243 - Assessment of Neutralizing Antibody in Participants from Phase I/II Trials of ALVAC-HIV (vCP-1521) Priming with Chiron gp12-B/E, Sanofi-Pasteur Oligomeric gp160, or AIDSVAX™ B/E gp120 B/E Boosting Against a Newly Developed, Standardized Panel of HIV-1	2008
RV254 (SEARCH010) - Establish and Characterize an Acute HIV Infection Cohort in a Thai High Risk Population SEARCH Studies	2009
RV262 - A Phase I study of the safety and immunogenicity of PENNVAX G DNA (env, gag, pol) with IL-15 DNA plasmid adjuvant administered by Intramuscular Biojector® 2000 injection followed by intramuscular MVA-CMDR (HIV-1 CM235 env/ CM240 gag/pol) boost in healthy, HIV uninfected adults	2011
RV269-003 - HCV	2010
RV269-006 - To determine the concentration, characterization, and neutralizing activity of mucosal and plasma antibodies from RV118/HSRRB Log #A-7856	2009
RV322 - Humoral Immunological assessment of RV135, a phase I/II of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming with VaxGen 120 B/E (AIDSVAX B/E) Boosting in Thai HIV-Seronegative Adults	2011
WR # 1498 (SEARCH 011) - Peripheral Reservoir of HIV DNA in Monocytes Pivotal to Cognition in HIV	2009
WR # 1505 (CDC # 4614) - HIV-1 Molecular Epidemiology in the Bangkok Men who have sex with Men (MSM) cohort study	2009
WR # 1587 - Study of full-length and partial HIV genetic sequences in seroconverting blood donors collected during September 2007-March 2008	2009
WR # 1617 - Characterization of humoral neutralizing activity in plasma of HIV individuals	2010
RV304 - Characteristics of immune cells in gut mucosa of HIV negative and chronically HIV-infected Thais	2012
RV305 - • RV305Randomized, Double Blind Evaluation of Late Boost Strategies for HIV-uninfected Participants in the HIV Vaccine Efficacy Trial RV144: Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming with VaxGen gp120 B/E (AIDSVAX® B/E) Boosting in HIV-uninfected Thai Adults	2012

Protocols, Future Planned

RV217 Rapid Vax Randomized, Double Blind Evaluation of Sanofi Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming and Global Solutions for Infectious Diseases (GSID) gp120 B/E (AIDSVAX® B/E) in an Accelerated Prime-Boost Regimen in HIV-uninfected Men who Have Sex with Men in Thailand

RV274 - Specimen Collection Procedures for Clinical Laboratory Quality Management Practices (Submitted to IRB)

RV306 - Randomized, Double Blind Evaluation of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming and Multiple Boosting Regimens with and without VaxGen gp120 B/E (AIDSVAX® B/E) in HIV-uninfected Thai Adults (Submitted for Scientific Review)

RV307 A Phase I Study of Prime-Boost Combinations Using Modified Vaccinia Ankara and Adenovirus Type 26 Vectors With Mosaic and Natural Inserts in Healthy, HIV-Uninfected Adults

RV310 - Randomized, Double Blind Evaluation of KI-DNA prime with MVA-CMDR boost in HIV-infected Thai Adults receiving HAART during acute phase infection - RV254 patients on mega HAART getting MVA vaccine (aborted)

RV320 - Quality of life assessment of HIV-infected volunteers, blood test result disclosure, and opinions of RV152 volunteers about the HIV vaccine trial result (Submitted for Scientific Review)

RV328 - Randomized, Double Blind Evaluation of Sequential Administrations of gp120 B/E (AIDSVAX® B/E) (GSID) with 1-Year Boosting in HIV-uninfected Thai Adults (Submitted for Scientific Review)

RV335 - Determination of the Quality, Quantity and Specificity of Antibodies in Mucosal Specimens Collected by the Thai Red Cross (Submitted to IRB)


RV348 - Longitudinal Study among Men who have Sex with Men at Risk for HIV-1 Infection to Determine Feasibility as a Cohort for a Future HIV Vaccine Trial

WR#1896 - Surveillance of HIV resistance transmission and new HIV recombinant forms in Thailand

WR#1912 - Molecular Characterization of HIV-1 in Female Sex Workers in Thailand

WR# 1921- Medical Quality Assurance on the Performance of HIV-1 Diagnostic Assays and HIV-1 Characterization

SEARCH 015 A Cohort Observational Study Evaluating Predictors, Incidence And Immunopathogenesis Of Immune Reconstitution Syndrome (IRIS) In HIV-1 Infected Patients With CD4 Count <100 Cells/ μ L Who Are Initiating Antiretroviral Therapy



Legends of the graphic displays:

- Department Chief
- 31 Completed Protocols
- 18 Ongoing Protocols
- 11 Planned Protocols
- 7 Aborted protocols

